Dr. Barrish is the Chief Scientific Officer at Achillion and has more than 30 years of experience in the pharmaceutical industry. For the last five years, Dr. Barrish was Vice President and Head of Discovery Chemistry at Bristol-Myers Squibb (BMS), leading chemical research on small molecules and other modalities across all therapeutic areas and sites. Prior to that role, he was responsible for teams at BMS that advanced more than 20 compounds into clinical development including SPRYCEL (dasatinib), a marketed kinase inhibitor used for the treatment of chronic myelogenous leukemia, which he co-invented. He and his co-inventors received the 2008 Thomas Alva Edison Patent Award for its discovery.
Dr. Barrish has co-authored over 120 peer-reviewed publications, is a co-inventor on more than 35 issued U.S. patents, and has been invited to give more than 40 lectures at international conferences and universities. In 2010, Dr. Barrish was elected to the Executive Committee of the American Chemical Society Medicinal Chemistry Division and served as its Chair in 2013. He was named an American Chemical Society Fellow in 2012. Dr. Barrish is also a Scientific Advisory Board member for the chemistry department at the University of Pennsylvania.
Dr. Barrish graduated summa cum laude in Chemistry from the University of Pennsylvania and received a doctorate in Organic Chemistry from Columbia University.